13.47 USD
▲-0.47+27.08%
盘后 10.58 -0.19%
2026-08-03
市值
$1.39B
市盈率
—
EPS
-1.35
股息率
—
52 周区间
7.23 – 14.93
成交量
5.04M
Beta
0.97
目标价
20.69
52W 低 7.2352W 高 14.93
价格走势
公司简介
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat...